Total Payments
$23,417
2024 Payments
$4,442
Companies
7
Transactions
40
Payment Breakdown by Category
Research$18,553 (79.2%)
Travel$3,361 (14.4%)
Food & Beverage$1,503 (6.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,553 | 7 | 79.2% |
| Travel and Lodging | $3,361 | 8 | 14.4% |
| Food and Beverage | $1,503 | 25 | 6.4% |
Payments by Type
Research
$18,553
7 transactions
General
$4,864
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $14,313 | 5 | $0 (2023) |
| Eli Lilly Export S.A. Puerto Rico Branch | $4,240 | 2 | $0 (2024) |
| Allergan Inc. | $2,630 | 22 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $1,835 | 6 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $149.78 | 2 | $0 (2024) |
| AbbVie Inc. | $129.88 | 2 | $0 (2023) |
| Tris Pharma Inc | $119.66 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,442 | 4 | Eli Lilly Export S.A. Puerto Rico Branch ($4,240) |
| 2023 | $1,016 | 5 | Eli Lilly and Company ($818.62) |
| 2022 | $10,123 | 2 | Eli Lilly and Company ($10,123) |
| 2021 | $3,372 | 1 | Eli Lilly and Company ($3,372) |
| 2018 | $2,630 | 22 | Allergan Inc. ($2,630) |
| 2017 | $1,835 | 6 | Novartis Pharmaceuticals Corporation ($1,835) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Janssen Pharmaceuticals, Inc | INVEGA (Drug) | Food and Beverage | In-kind items and services | $82.04 | General |
| Category: Neuroscience | ||||||
| 09/23/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $2,255.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 09/23/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $1,985.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 03/21/2024 | Tris Pharma Inc | Dyanavel XR (Drug), Quillivant, Quillichew ER | Food and Beverage | In-kind items and services | $119.66 | General |
| Category: ADHD | ||||||
| 11/02/2023 | Janssen Pharmaceuticals, Inc | INVEGA (Drug) | Food and Beverage | In-kind items and services | $67.74 | General |
| Category: Neuroscience | ||||||
| 08/28/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.93 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $124.95 | General |
| Category: NEUROSCIENCE | ||||||
| 03/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $379.02 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $439.60 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/25/2022 | Eli Lilly and Company | — | — | In-kind items and services | $2,261.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 01/18/2022 | Eli Lilly and Company | — | — | In-kind items and services | $7,862.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 03/01/2021 | Eli Lilly and Company | — | — | In-kind items and services | $3,371.62 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 07/19/2018 | Allergan Inc. | VRAYLAR (Drug) | Travel and Lodging | Cash or cash equivalent | $268.85 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $124.12 | General |
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $34.82 | General |
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $32.81 | General |
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $17.51 | General |
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $16.31 | General |
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $16.31 | General |
| 07/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $16.31 | General |
| 07/18/2018 | Allergan Inc. | VRAYLAR (Drug) | Travel and Lodging | Cash or cash equivalent | $268.85 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2018 | Allergan Inc. | VRAYLAR (Drug) | Travel and Lodging | In-kind items and services | $871.18 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2018 | Allergan Inc. | VRAYLAR (Drug) | Travel and Lodging | Cash or cash equivalent | $197.89 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2018 | Allergan Inc. | VRAYLAR (Drug) | Travel and Lodging | Cash or cash equivalent | $186.50 | General |
| Category: NEUROSCIENCE | ||||||
| 04/23/2018 | Allergan Inc. | VRAYLAR (Drug) | Travel and Lodging | Cash or cash equivalent | $194.89 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $7,862 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $5,633 | 2 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly Export S.A. Puerto Rico Branch | $2,255 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly Export S.A. Puerto Rico Branch | $1,985 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $439.60 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $379.02 | 1 |
About Dr. Yvette Cruz, M.D
Dr. Yvette Cruz, M.D is a Psychiatry healthcare provider based in San Juan, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558300616.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yvette Cruz, M.D has received a total of $23,417 in payments from pharmaceutical and medical device companies, with $4,442 received in 2024. These payments were reported across 40 transactions from 7 companies. The most common payment nature is "" ($18,553).
Ad
Practice Information
- Specialty Psychiatry
- Location San Juan, PR
- Active Since 06/05/2006
- Last Updated 12/21/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1558300616
Products in Payments
- VRAYLAR (Drug) $2,118
- CNP520 (Drug) $1,161
- INVEGA (Drug) $149.78
- Dyanavel XR (Drug) $119.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in San Juan
Dr. Ileana Fumero, M.d, M.D
Psychiatry — Payments: $136,781
Psychiatry $136,781
Jose Alonso Alonso, Psychiatrist Md, PSYCHIATRIST MD
Psychiatry — Payments: $92,975
Psychiatry $92,975
Dr. Ivonne Vicente, M.d, M.D
Psychiatry — Payments: $19,822
Psychiatry $19,822
Dr. Myrangelisse Rios, Md, MD
Psychiatry — Payments: $9,120
Psychiatry $9,120
Dr. Karen Martinez-Gonzalez, Md, MD
Psychiatry — Payments: $6,599
Psychiatry $6,599
Dr. Fernando Martinez Scmidt, M.d, M.D
Psychiatry — Payments: $3,727
Psychiatry $3,727